RXRX vs SDGR
RXRX and SDGR side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RXRXRECURSION PHARMACEUTICALS, INC. | SDGRSchrodinger, Inc. |
|---|---|---|
| Revenue | — | $254.91M(TTM) |
| Revenue growth (YoY) | 26.9% | 23.3% |
| Net income | — | -$103.48M(TTM) |
| Earnings growth (YoY) | -39.1% | 44.8% |
| EPS, diluted | — | $-1.40(TTM) |
| EBIT margin | -867.9% | -65.2% |
| ROE | -62.9% | -32.9% |
| ROIC | -174.7% | — |
| 1y total return | -49.6% | -25.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: RXRX vs SDGR
| Metric | RXRX | SDGR |
|---|---|---|
| End value | $958 | $1.9K |
| Total return | -90.4% | -80.6% |
| CAGR | -35.8% | -26.6% |
| Volatility | 92.9% | 62.4% |
| Sharpe | -0.08 | -0.25 |
| Sortino | -0.12 | -0.37 |
| Max drawdown | -93.1% | -86.0% |
Based on 1329 common trading days, 2021-04-16 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)